167 related articles for article (PubMed ID: 18694543)
21. The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis.
Jansen JP; Bergman GJ; Huels J; Olson M
Semin Arthritis Rheum; 2011 Feb; 40(4):275-84.e1-2. PubMed ID: 20828791
[TBL] [Abstract][Full Text] [Related]
22. Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement.
Anagnostis P; Paschou SA; Mintziori G; Ceausu I; Depypere H; Lambrinoudaki I; Mueck A; Pérez-López FR; Rees M; Senturk LM; Simoncini T; Stevenson JC; Stute P; Trémollieres FA; Goulis DG
Maturitas; 2017 Jul; 101():23-30. PubMed ID: 28539165
[TBL] [Abstract][Full Text] [Related]
23. Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis.
Felsenberg D; Miller P; Armbrecht G; Wilson K; Schimmer RC; Papapoulos SE
Bone; 2005 Nov; 37(5):651-4. PubMed ID: 16126016
[TBL] [Abstract][Full Text] [Related]
24. Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study.
Harris ST; Reginster JY; Harley C; Blumentals WA; Poston SA; Barr CE; Silverman SL
Bone; 2009 May; 44(5):758-65. PubMed ID: 19168160
[TBL] [Abstract][Full Text] [Related]
25. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies.
Boonen S; Laan RF; Barton IP; Watts NB
Osteoporos Int; 2005 Oct; 16(10):1291-8. PubMed ID: 15986101
[TBL] [Abstract][Full Text] [Related]
26. Drug insight: Bisphosphonates for postmenopausal osteoporosis.
Chapurlat RD; Delmas PD
Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):211-9; quiz following 238. PubMed ID: 16932286
[TBL] [Abstract][Full Text] [Related]
27. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
Rossini M; Viapiana O; Gatti D; Adami S
Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
[TBL] [Abstract][Full Text] [Related]
28. Osteoporosis Treatment Efficacy for Men: A Systematic Review and Meta-Analysis.
Nayak S; Greenspan SL
J Am Geriatr Soc; 2017 Mar; 65(3):490-495. PubMed ID: 28304090
[TBL] [Abstract][Full Text] [Related]
29. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Wells GA; Cranney A; Peterson J; Boucher M; Shea B; Robinson V; Coyle D; Tugwell P
Cochrane Database Syst Rev; 2008 Jan; (1):CD001155. PubMed ID: 18253985
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis.
Saito T; Sterbenz JM; Malay S; Zhong L; MacEachern MP; Chung KC
Osteoporos Int; 2017 Dec; 28(12):3289-3300. PubMed ID: 28770272
[TBL] [Abstract][Full Text] [Related]
31. Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies.
Jansen JP; Bergman GJ; Huels J; Olson M
Curr Med Res Opin; 2009 Aug; 25(8):1861-8. PubMed ID: 19530978
[TBL] [Abstract][Full Text] [Related]
32. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
[TBL] [Abstract][Full Text] [Related]
33. Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women.
Sawka AM; Papaioannou A; Adachi JD; Gafni A; Hanley DA; Thabane L
BMC Musculoskelet Disord; 2005 Jul; 6():39. PubMed ID: 16008835
[TBL] [Abstract][Full Text] [Related]
34. Risedronate for the prevention and treatment of postmenopausal osteoporosis.
Cranney A; Waldegger L; Zytaruk N; Shea B; Weaver B; Papaioannou A; Robinson V; Wells G; Tugwell P; Adachi JD; Guyatt G
Cochrane Database Syst Rev; 2003; (4):CD004523. PubMed ID: 14584020
[TBL] [Abstract][Full Text] [Related]
35. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
[TBL] [Abstract][Full Text] [Related]
36. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
Pyon EY
Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
[TBL] [Abstract][Full Text] [Related]
37. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
Ettinger MP
Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
[TBL] [Abstract][Full Text] [Related]
38. Vitamin K to prevent fractures in older women: systematic review and economic evaluation.
Stevenson M; Lloyd-Jones M; Papaioannou D
Health Technol Assess; 2009 Sep; 13(45):iii-xi, 1-134. PubMed ID: 19818211
[TBL] [Abstract][Full Text] [Related]
39. Bisphosphonates for Paget's disease of bone in adults.
Corral-Gudino L; Tan AJ; Del Pino-Montes J; Ralston SH
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD004956. PubMed ID: 29192423
[TBL] [Abstract][Full Text] [Related]
40. Bazedoxifene versus oral bisphosphonates for the prevention of nonvertebral fractures in postmenopausal women with osteoporosis at higher risk of fracture: a network meta-analysis.
Ellis AG; Reginster JY; Luo X; Cappelleri JC; Chines A; Sutradhar S; Jansen JP
Value Health; 2014 Jun; 17(4):424-32. PubMed ID: 24969003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
